Strong efficacy for patients starting or switching therapy
Well-understood safety profile
Flexibility of a treatment that can go everywhere they go
The efficacy of VUMERITY is based upon bioavailability studies comparing DMF to VUMERITY in patients with relapsing forms of MS and healthy subjects2
In Study 1 and Study 2 pivotal trials, DMF demonstrated a 53% and 44% relative reduction in annualized relapse rate (ARR) vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)2
VUMERITY offers your patients:
Efficacy and safety outcomes from a study of patients who switched to VUMERITY